ATC Group: G02AD03 Gemeprost

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of G02AD03 in the ATC hierarchy

Level Code Title
1 G Genito urinary system and sex hormones
2 G02 Other gynecologicals
3 G02A Oxytocics
4 G02AD Prostaglandins
5 G02AD03 Gemeprost

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
VAGIN - Vaginal 1 mg

Active ingredients in G02AD03

Active Ingredient Description
Gemeprost

Gemeprost (16, 16-dimethyl-trans-delta2 PGE1 methyl ester) is a prostaglandin E1 analogue. Both in pregnant and non-pregnant animals, it causes contraction of the uterus and causes softening and decreases resistance of cervical tissue. Gemeprost depresses placental and uterine blood flow but those actions are secondary to the main uterine stimulation.

Related product monographs

Title Information Source Document Type  
CERVAGEM Vaginal pessary Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC

Medicines in this ATC group

France (FR)

Japan (JP)

Singapore (SG)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.